nDatalyze hires Venture Play for YMI marketing campaign
Calgary, AB – TheNewswire – March 30, 2022 – nDatalyze Corp. (“NDAT“or the”society”) (CSE:NDAT) (CNSX:NDAT.CN) (OTC: NDATF) is pleased to announce that it has engaged (the “Engagement”) Venture Play to formulate the Company’s marketing strategy and program related to the upcoming launch of the advanced machine learning mental health diagnostic tool YMI of the society.
NDAT President Jim Durward says, “We have previously engaged Venture Play to conduct a primary market research program and have been impressed with the outcome. This new engagement envisions Venture Play developing a comprehensive marketing program for YMI and we are confident that the result will be a progressive program that meets the needs of consumers in the face of the ongoing mental health crisis.Engagement is an independent, third-party, all-cash arrangement – there is no NDAT actions involved.
The Company further reports that the YMI application continues to improve its user experience (“UX”) upgrades in response to its ongoing beta testing and that beta testing is expected to be open to the public in the near future. Currently, five of the seven mental disorders are operational, with the last two expected before the end of April 2022.
About Venture Play:
Venture Play is part of Venturepark, a leading business growth ecosystem led by business, capital, brand, culture and CPG specialists. Founded by investor and entrepreneur Arlene Dickinson, Venturepark touches all aspects of business to fund, create, scale, reinvent and drive business growth.
About nDatalyze Corp. :
nDatalyze Corp. generates technological solutions related to health. The YMI division is developing a consumer mental health application based on machine learning and the MLdelic division is focusing on the application of machine learning to aid in the prediction of potential benefits associated with the use of natural compounds in the mental health sector. Both YMI and MLdelic are based on the company’s proprietary reference database of over 1,200 biometric records, including “same time of day” EEG data. With facilities around the world, its Medxtractor division manufactures small-scale bio-extractors that are used to extract compounds from a variety of botanical biomasses. While the Medxtractor division is currently generating cash flow, the two YMI and MLdelic are in development and therefore the Company cannot accurately predict if or when these applications will become cash flow generating.
FOR MORE INFORMATION, PLEASE CONTACT:
James Durward, President and CEO
Phone: (403) 689-3901
E-mail: email@example.com Website: www.ndatalyze.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer to sell or a solicitation of an offer to sell any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “United States Securities Act”) or any state securities law and may not be offered or sold in the United States or to US persons unless registered under United States securities law and applicable state securities laws or an exemption from such registration is available.
The information in this press release includes certain information and statements about management’s views on future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based on assumptions subject to significant risks and uncertainties. Due to these risks and uncertainties and due to various factors, actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. A number of factors could cause actual results to differ materially from these forward-looking statements and from future results. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the expectations in the forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and undertakes no obligation to update or revise forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting these forward-looking statements or otherwise.